Saturday 17 October 2026
Export NKTR’s income statement to Excel — free account
Nektar Therapeutics
NKTR Healthcare Biotechnology
Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.
35.78
1.94
−5.14%
Follow NKTR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
42.27 | 31.99 | 12.91 | 17.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(30.45) | (40.18) | (10.98) | (22.11) | |
P/B ratio |
2.56 | 3.09 | 7.94 | 12.67 | |
Price to Tangible BV |
2.57 | 3.12 | 8.42 | 13.49 | |
EV/Sales |
38.94 | 30.80 | 17.56 | 20.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.09) | (8.41) | (4.65) | (6.91) | |
EV/FCF |
(9.08) | (8.40) | (4.65) | (6.88) | |
Quick Ratio |
9.64 | 9.85 | 4.59 | 4.07 | |
Current Ratio |
10.42 | 10.21 | 4.97 | 4.24 | |
Net Debt/EBITDA |
14.96 | 14.02 | 10.30 | 8.21 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.08 | 0.11 | 0.19 | 0.21 | |
Operating CF/Net income |
1.87 | 0.99 | 1.80 | 1.37 | |
Capex/Depreciation |
0.03 | 0.01 | 0.00 | 0.09 | |
Interest Coverage |
(5.88) | (4.92) | (2.83) | (5.24) | |
Research and Development Expense of Revenue |
386.23% | 328.51% | 136.25% | 231.15% | |
Selling, General and Administrative Expense of Revenue |
126.00% | 123.74% | 51.29% | 136.30% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.02 | |
Share Based Compensation of Revenue |
33.21% | 30.89% | 10.06% | 26.06% | |
Graham Net Nets |
0.24 | 0.23 | 0.11 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.60%) | (11.70%) | (24.12%) | (14.00%) | |
Free Cash Flow Yield |
(10.14%) | (11.46%) | (29.26%) | (17.66%) | |
Revenue per Share |
0.31 | 0.44 | 1.29 | 0.62 | |
Operating CF per Share |
(2.29) | (1.79) | (3.85) | (2.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(2.30) | (1.79) | (3.85) | (2.58) | |
Cash per Share |
20.70 | 22.99 | 14.57 | 14.26 | |
Shareholders Equity per Share |
27.32 | 23.29 | 5.32 | 4.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.32 | 23.29 | 5.32 | 4.49 | |
Free Cash Flow |
(75.86) | (44.32) | (64.98) | (48.87) | |
Working Capital |
668.42 | 531.33 | 212.73 | 215.02 | |
Capital Expenditures |
(0.09) | (0.02) | (0.02) | (0.11) | |
Net Current Asset Value |
547.39 | 401.99 | 75.69 | 65.10 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
19.59 | 13.93 | 11.17 | 12.07 | |
Average Assets |
651.33 | 509.76 | 292.13 | 304.66 | |
Average Common Equity |
439.46 | 294.98 | 75.28 | 66.99 |
Columns are period end dates